Genitourinary Cancers

From the NBA’s Alonzo Mourning opening up about his prostate surgery to an actor from “Felicity” dying of cancer, here’s what is happening in the oncology space this week.

Keytruda plus platinum-based chemotherapy appeared to be safe and effective in treating penile squamous cell carcinoma.

For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery.

Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%.

During my time with cancer, I've come across words associated with cancer that I don't like and some that I appreciate.

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.

Whole-pelvic radiation conferred a 67% lower risk of all-cause mortality among patients younger than 65 with unfavorable-risk prostate cancer.

From Olivia Munn opening up about undergoing a hysterectomy and egg retrieval to Michael McDonald’s learned lesson after his wife’s cancer, here’s what’s going on in the oncology space this week.

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.

A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive bladder cancer.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects.

After recovering from testicular cancer, I feel as though I've earned a second life where I face my fears head-on.

A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer.

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

The survival benefit observed with Padcev plus Keytruda was “unlike anything we’d seen before” for advanced bladder cancer, according to an expert.

From the Allman Brothers Band’s singer Dickey Betts dying after a cancer diagnosis to the “Shopaholic” author announcing her glioblastoma diagnosis, here’s what is happening in the cancer space this week.

Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

Compared to other treatments, patients’ testosterone levels return to baseline levels faster following treatment with Orgovyx.

Anxiety over scans makes sense, but isn’t there more anxiety about other cancer tests, too?

Patients with prostate cancer receiving ADT who are vitamin D deficient may receive the most bone density benefits from high-dose vitamin D.

When experiencing loss, always look forward and have hope.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

Treatment with immune checkpoint inhibitors has improved survival outcomes for patients with metastatic bladder cancer, compared with chemotherapy.

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

When life hands you cancer lemons, what flavored lemonade do you make?